2. Search Result
Search Result
Results for "

learning. memory

" in MedChemExpress (MCE) Product Catalog:

68

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

9

Natural
Products

1

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0764
    Bucladesine sodium
    Maximum Cited Publications
    41 Publications Verification

    Dibutyryl cAMP sodium; DBcAMP sodium

    		 PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine sodium
  • HY-115864
    Osavampator

    TAK-653; NBI-1065845

    		 iGluR Lipoxygenase Neurological Disease
    Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .
    Osavampator
  • HY-W011370
    Pelargonidin chloride
    1 Publications Verification

    		 Quinone Reductase Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Pelargonidin chloride is an anthocyanidin and also is a scavenger of nitric oxide radical and has antioxidant activities. Pelargonidin inhibits cell viability and induces cell cycle arrest at sub-G1 phase. Pelargonidin chloride increases the mRNA and protein expression of HO-1, NQO1, Nrf2. Pelargonidin chloride improves Aβ-induced memory and learning impairment .
    Pelargonidin chloride
  • HY-100784
    Dihydrokainic acid
    1 Publications Verification

    		 EAAT Neurological Disease
    Dihydrokainic acid is a glutamate transporters (especially GLT1) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory .
    Dihydrokainic acid
  • HY-B0978
    Diethyltoluamide

    DEET; N,N-Diethyl-m-toluamide

    		 Environmental Pollutants Parasite Infection Neurological Disease
    Diethyltoluamide (DEET) is the most common active ingredient in insect repellents. It is intended to provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects. Diethyltoluamide is toxic to hepatocytes and can lead to many physiological, pharmacological, and behavioral abnormalities, particularly motor deficits and learning and memory dysfunction .
    Diethyltoluamide
  • HY-131892
    2-Deoxy-D-galactose
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease Cancer
    2-Deoxy-D-galactose is a glucose analog. 2-Deoxy-D-galactose inhibits glycolysis to inhibits tumor growth. 2-Deoxy-D-galactose is a substance interfering with the fucosylation of glycomacromolecules and impairing memory consolidation in various learning tasks. 2-Deoxy-d-galactose hinders glycoprotein fucosylation in vivo .
    2-Deoxy-D-galactose
  • HY-N2183
    Baimaside
    3 Publications Verification

    Quercetin 3-O-sophoroside

    		 SARS-CoV Infection Neurological Disease
    Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to SARS-CoV-2-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of SARS-CoV-2 and its variants, making it suitable for research related to Alzheimer's disease and COVID-19 .
    Baimaside
  • HY-B0764A
    Bucladesine hemicalcium
    Maximum Cited Publications
    41 Publications Verification

    Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium

    		 PKA Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine hemicalcium
  • HY-NP0204
    Mouse Serum Albumin

    		ELOVL Apoptosis NOD-like Receptor (NLR) Caspase Tau Protein Neurological Disease Inflammation/Immunology
    Mouse Serum Albumin is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD) .
    Mouse Serum Albumin
  • HY-B2167R
    Docosahexaenoic acid (Standard)

    DHA (Standard); Cervonic acid (Standard)

    		 Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC50 for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .
    Docosahexaenoic acid (Standard)
  • HY-B0106A
    Etiracetam

    UCB 6474

    		 Drug Derivative Neurological Disease
    Etiracetam is a racetam-class nootropic agent. Etiracetam enhances learning and memory in both normal and amnesic rats. Etiracetam can be used in studies related to memory retrieval disorders and amnesic diseases such as Alzheimer's disease .
    Etiracetam
  • HY-N0541
    Pseudoginsenoside F11
    2 Publications Verification

    Ginsenoside A1

    		 Endogenous Metabolite Others
    Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.
    Pseudoginsenoside F11
  • HY-17553
    Coluracetam
    3 Publications Verification

    MKC-231

    		 iGluR Neurological Disease
    Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .
    Coluracetam
  • HY-123037
    Triadimefon

    		Environmental Pollutants AMPK Akt PERK Fungal Infection Neurological Disease Metabolic Disease Endocrinology
    Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory .
    Triadimefon
  • HY-118424
    JNJ-55511118

    		iGluR Neurological Disease Metabolic Disease
    JNJ-55511118 is a selective TARP γ-8 binding AMPA receptor modulator with oral bioavailability and blood-brain barrier permeability, with a Ki of 26 nM. JNJ-55511118 reduces voluntary intake of sweetened alcohol in male mice. In rodent models, JNJ-55511118 inhibits hippocampal neurotransmission, reduces specific electroencephalogram frequency bands, induces transient hyperlocomotion, impairs learning and memory abilities, and exerts anticonvulsant effects. JNJ-55511118 is applicable to research related to alcohol use disorder and seizures .
    JNJ-55511118
  • HY-P99216
    Ponezumab
    1 Publications Verification

    PF-04360365; RN 1219

    		 Amyloid-β Neurological Disease
    Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
    Ponezumab
  • HY-B1752
    Quinpirole
    4 Publications Verification

    LY 171555; (-)-LY 141865

    		 Dopamine Receptor Calcium Channel Bcl-2 Family iGluR Apoptosis Neurological Disease
    Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .
    Quinpirole
  • HY-100406
    (S)-MCPG
    1 Publications Verification

    (+)-MCPG

    		 mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371) . (S)-MCPG can be used for the study of the function of mGluRs in spatial learning .
    (S)-MCPG
  • HY-17549
    Adrafinil

    CRL 40028

    		 Adrenergic Receptor Neurological Disease
    Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
    Adrafinil
  • HY-N1414
    (E)-3',6-Disinapoylsucrose

    		Trk Receptor NF-κB Amyloid-β Neurological Disease
    (E)-3',6-Disinapoylsucrose is an orally active, blood-brain barrier permeable neuroprotective agent that inhibits Aβ protein aggregation. (E)-3',6-Disinapoylsucrose exerts anxiolytic, anti-inflammatory and cognitive-enhancing effects. (E)-3',6-Disinapoylsucrose regulates the TrkB/BDNF signaling pathway, inhibits the expression of NF-κB p65, reduces pro-inflammatory cytokine levels, and alleviates neuronal damage. (E)-3',6-Disinapoylsucrose also enhances the functions of central 5-HT and noradrenergic systems, thereby improving spatial learning and memory abilities and reducing anxiety-like behaviors. (E)-3',6-Disinapoylsucrose can be used for the research of related diseases such as Alzheimer's disease, depression, memory impairment and anxiety disorder .
    (E)-3',6-Disinapoylsucrose
  • HY-B1953
    Thiacloprid
    1 Publications Verification

    		 Environmental Pollutants Insecticide nAChR Infection
    Thiacloprid is an orally active neurotoxic insecticide and also a nAChR agonist. Thiacloprid reduces the viability of healthy cells, depletes reduced glutathione, and increases MDA levels, thereby inducing cytotoxicity and oxidative stress damage. In practical applications, Thiacloprid has lower acute toxicity to honeybees than other compounds of the same class such as Imidacloprid (HY-B0838), but it still significantly impairs the learning and memory function, immune capacity and survival status of honeybees. Thiacloprid induces intestinal microbial dysbiosis and reduces survival rate in middle-aged honeybees, increases the risk of premature collapse in bumblebee colonies, and significantly decreases the final colony weight and reproductive output. Thiacloprid is used in broad-spectrum agricultural pest control, often alone or in combination with Deltamethrin (HY-B1971), and meets the pest management needs of various crops including potatoes, cabbages, various fruits and vegetables, and nuts .
    Thiacloprid
  • HY-146086
    Nrf2 activator-4

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology
    Nrf2 activator-4 (Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 µM. Nrf2 activator-4 suppresses reactive oxygen species against oxidative stress in microglia. Nrf2 activator-4 effectively recovers the learning and memory impairment in a scopolamine-induced mouse model .
    Nrf2 activator-4
  • HY-B0764B
    Bucladesine

    Dibutyryl cAMP; DBcAMP

    		 PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine
  • HY-N0459
    3,5-O-Dicaffeoylquinic acid
    1 Publications Verification

    		 Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid
  • HY-B0978R
    Diethyltoluamide (Standard)

    DEET (Standard); N,N-Diethyl-m-toluamide (Standard)

    		 Reference Standards Parasite Infection Neurological Disease
    Diethyltoluamide (Standard) is the analytical standard of Diethyltoluamide. This product is intended for research and analytical applications. Diethyltoluamide (DEET) is the most common active ingredient in insect repellents. It is intended to provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects. Diethyltoluamide is toxic to hepatocytes and can lead to many physiological, pharmacological, and behavioral abnormal ities, particularly motor deficits and learning and memory dysfunction .
    Diethyltoluamide (Standard)
  • HY-B0764G
    Bucladesine sodium

    Dibutyryl cAMP sodium; DBcAMP sodium

    		 PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine sodium
  • HY-139583
    Sunobinop

    S 117957; IMB 115

    		 Opioid Receptor Neurological Disease
    Sunobinop (S 117957; IMB 115) is an orally active and blood-brain barrier-permeable selective partial agonist of the human nociceptin/orphanin FQ receptor (NOP), which exhibits high affinity for human targets (Ki=3.3 nM; EC50=4.03 nM; Emax=47.8%) without activating μ and κ opioid receptors. Sunobinop significantly reduces wakefulness time and increases non-rapid eye movement sleep in rats by activating NOP receptors, and produces no significant side effects on learning, memory, reward, respiration or intestinal function at effective doses. Sunobinop displays competitive antagonist properties in specific signaling pathways, such as β-arrestin 2 recruitment. With these unique pharmacological properties, Sunobinop can be used to investigate insomnia, moderate-to-severe alcohol use disorder, and urinary incontinence caused by overactive bladder .
    Sunobinop
  • HY-135525
    Agroclavine

    		Dopamine Receptor Adrenergic Receptor Neurological Disease Inflammation/Immunology
    Agroclavine acts as an agonist of the D1-dopamine receptor and α1-adrenergic receptor. Agroclavine enhances the sensitivity of the brain to magnetic fields; it impairs spatial memory without affecting hippocampal long-term potentiation (LTP). Agroclavine exerts bidirectional regulatory effects on immune activity: it enhances NK cell activity with low toxicity under normal conditions, while it inhibits NK cell activity and exhibits significant cardiac and hepatic toxicity under stress conditions. Agroclavine can be used for research on neuroelectrophysiology, learning and memory, and immunoregulation .
    Agroclavine
  • HY-P10506
    CMX-8933

    		JNK Neurological Disease
    CMX-8933 is an octapeptide fragment of the goldfish brain neurotrophic factor ependymin. CMX-8933 increases the enzymatic activity of c-Jun N-terminal kinase (JNK), increases the phosphorylation of JNK and c-Jun proteins, and increases the cellular levels of c-Jun and c-Fos mRNA. CMX-8933 can be used to study the role of ependymin in neuroplasticity, learning, memory formation, and neural regeneration .
    CMX-8933
  • HY-148325
    α7 Nicotinic receptor agonist-1

    		nAChR Neurological Disease
    α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .
    α7 Nicotinic receptor agonist-1
  • HY-135483A
    AR-R17779 hydrochloride

    		nAChR Neurological Disease
    AR-R17779 hydrochloride is a potent and selective full agonist of nAChR, with Kis of 92 and 16000 nM for α7 and α4β2 subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .
    AR-R17779 hydrochloride
  • HY-W987949
    Z-4105

    		Others Neurological Disease
    Z-4105 is an orally active nootropic agent. Z-4105 reverses the amnesic effects of electroconvulsive shock (ECS) and methylazoxymethanol acetate (MAM), and improves learning and memory functions. Z-4105 enhances the activity of the brain cholinergic system without affecting other neurotransmitter systems. Z-4105 significantly alleviates neuropathic pain in rats. Z-4105 can be used in the research of neuropathic pain and brain dysfunction .
    Z-4105
  • HY-142701
    SSTR4 agonist 4

    		Somatostatin Receptor Neurological Disease
    SSTR4 agonist 4 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .
    SSTR4 agonist 4
  • HY-B0764R
    Bucladesine sodium (Standard)

    Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)

    		 Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine sodium (Standard)
  • HY-P3684A
    [DPro5] Corticotropin Releasing Factor, human, rat TFA

    		CRFR Neurological Disease
    [DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat TFA
  • HY-155126
    LZWL02003

    		Reactive Oxygen Species (ROS) Neurological Disease
    LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP +-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .
    LZWL02003
  • HY-124086
    BHQ-O-5HT

    		5-HT Receptor Neurological Disease
    BHQ-O-5HT is a light-activated caged 5-HT protected by a BHQ group. When exposed to light at 365 or 740 nm, BHQ-O-5HT releases 5-HT through 1 or 2 photon excitation, respectively. BHQ-O-5HT can be manipulated in space and time to explore the role of 5-HT in regulating mood, appetite, memory, learning, and other cognitive functions .
    BHQ-O-5HT
  • HY-123037R
    Triadimefon (Standard)

    		Reference Standards Fungal Akt PERK AMPK Infection Neurological Disease Metabolic Disease Endocrinology
    Triadimefon (Standard) is the analytical standard of Triadimefon (HY-123037). This product is intended for research and analytical applications. Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory .
    Triadimefon (Standard)
  • HY-124244
    DB-959

    PPARδ/γ agonist 1

    		 PPAR Neurological Disease
    DB-959 (PPARδ/γ agonist 1) is a potent PPAR agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD). .
    DB-959
  • HY-141541
    MPT0G413

    		HDAC Tau Protein Neurological Disease
    MPT0G413 (Compound 6) is a potent, selective, orally active and brain-penetrant HDAC6 inhibitor with an IC50 of 3.92 nM. MPT0G413 decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. MPT0G413 can ameliorate the impaired learning and memory. MPT0G413 can be used for the research of neurological disease, such as Alzheimer's disease .
    MPT0G413
  • HY-142700
    SSTR4 agonist 3

    		Somatostatin Receptor Neurological Disease
    SSTR4 agonist 3 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .
    SSTR4 agonist 3
  • HY-179363
    BChE-IN-46

    		Cholinesterase (ChE) COX Neurological Disease
    BChE-IN-46 is a selective and brain-penetrant BChE inhibitor (eqBChE IC50 = 7.44 × 10 −5 μM, SI > 270,000; hBChE, IC50 = 1.48 × 10 −3 μM). BChE-IN-46 has COX-2 inhibitory activity (IC50 = 0.11 μM). BChE-IN-46 exhibits neuroprotective effects, enhances acetylcholine levels, and alleviates cognitive deficits, anxiety, and learning/memory impairments. BChE-IN-46 can be used for the development of anti-Alzheimer's disease drugs .
    BChE-IN-46
  • HY-B1953R
    Thiacloprid (Standard)

    		Reference Standards nAChR Insecticide Infection
    Thiacloprid (Standard) is the analytical standard of Thiacloprid. This product is intended for research and analytical applications. Thiacloprid is an orally active neurotoxic insecticide and also a nAChR agonist. Thiacloprid reduces the viability of healthy cells, depletes reduced glutathione, and increases MDA levels, thereby inducing cytotoxicity and oxidative stress damage. In practical applications, Thiacloprid has lower acute toxicity to honeybees than other compounds of the same class such as Imidacloprid (HY-B0838), but it still significantly impairs the learning and memory function, immune capacity and survival status of honeybees. Thiacloprid induces intestinal microbial dysbiosis and reduces survival rate in middle-aged honeybees, increases the risk of premature collapse in bumblebee colonies, and significantly decreases the final colony weight and reproductive output. Thiacloprid is used in broad-spectrum agricultural pest control, often alone or in combination with Deltamethrin (HY-B1971), and meets the pest management needs of various crops including potatoes, cabbages, various fruits and vegetables, and nuts .
    Thiacloprid (Standard)
  • HY-117984
    RU 35929

    		Drug Derivative Neurological Disease
    RU 35929 is a nootropic agent. RU 35929 enhances learning and memory .
    RU 35929
  • HY-19692
    Itasetron

    DA 6215; U98079A

    		 5-HT Receptor Neurological Disease
    Itasetron (DA 6215) is a selective 5-HT3 receptor antagonist. Itasetron improves spatial learning and memory abilities in the aged rat. Itasetron has potent antiemetic properties. Itasetron is used for age-related memory degeneration in rodents .
    Itasetron
  • HY-119061
    SB357134

    		5-HT Receptor Neurological Disease
    SB-357134 is a potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist. SB-357134 enhances memory and learning and increases seizure threshold in rats .
    SB357134
  • HY-122150
    AMPA receptor modulator-3

    		iGluR Neurological Disease
    AMPA receptor modulator-3 is an allosteric AMPA receptor modulator (EC50: 4.4 μM). AMPA receptor modulator-3 can be used in the research of mammalian nervous system, such as learning and memory .
    AMPA receptor modulator-3
  • HY-N0459R
    3,5-O-Dicaffeoylquinic acid (Standard)

    		Reference Standards Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,5-O-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid (Standard)
  • HY-143464
    BChE-IN-4

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-4 is a potent and cross the blood-brain barrier BChE inhibitor. BChE-IN-4 attenuates learning and memory deficits caused by cholinergic deficit in mouse model. BChE-IN-4 has the potential for the research of alzheimer’s disease .
    BChE-IN-4
  • HY-P3684
    [DPro5] Corticotropin Releasing Factor, human, rat

    		CRFR Endocrinology
    [DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: